Alpha Compute Corp · NASDAQ:ALP
Alpha Compute — Portage Biotech — Investor Presentation (March 2023)
24 slides from Alpha Compute's investor presentation, Mar 14, 2023
Slide 1: Corporate Presentation
Corporate Presentation 1 Nasdaq: PRTG March 2023
Slide 2: Legal Disclaimer
Legal Disclaimer 2 This presentation is for information purposes only . This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction . Such an offer can only be made by prospectus or other author
Slide 3: Investment Highlights
Immuno - Oncology Company with Four First/Best in Class Compounds in the Clinic Investment Highlights Cost - Efficient Business Model, Potential Runway to Achieve Multiple Inflection Points Multiple Phase 1b/2 Data Catalysts in 2023 and 2024 Experienced Leadership Team from Bristol Myers Squibb 3
Slide 4: Proven Leadership with Oncology and Financing Expertise
Allan Shaw CFO Justin Fairchild VP Clin Dev Proven Leadership with Oncology and Financing Expertise Board of Directors Gregory Bailey, MD Rob Glassman, MD Linda M. Kozick Jim Mellon Mark Simon Ian Walters, MD CEO, Chairman Rob Kramer, PhD CSO Steve Innaimo VP PM & Operations Brian Wiley CBO Steven M
Slide 5: Our Formula for Success
Our Formula for Success De - Risked Development Structured to Create Significant Value Strong Academic & Industry Network First/Best in Class I/O Agents Potential for Large Returns • Compounds with broad targets, single agent activity • Address ~70 - 80% of patients that don’t respond 5 • Randomized
Slide 6: Nine Phase 1b/2 Data Catalysts Anticipated to Drive Value
Nine Phase 1b/2 Data Catalysts Anticipated to Drive Value iNKT Engager Platform Adenosine Plat PLATFORM INDICATION STAGE # of PTS Interim Data Final Data PORT - 2 Melanoma + NSCLC Phase 1 18 ASCO 23 SITC 2023 PORT - 3 Solid Tumors Phase 1 12 ESMO 2023 ᬚ PORT - 2+ Keytruda ® Refractory Melanoma Phase
Slide 7: iNKT Engagers PORT-2, PORT-3
iNKT Engagers PORT - 2, PORT - 3 Activating the innate, adaptive immune system and correcting the TME
Slide 8: Portage's iNKT Agonist (PORT-2): Liposomal Formulation of IMM60
Portage’s iNKT Agonist (PORT - 2): Rationally Designed Liposomal Formulation of IMM60 iNKT in charged liposome to protect lipid chain, aggregate in tumor, and promote Type 1 cytokine release iNKT cell IMM60 Binds to CD1d on APC and other myeloid cells TCR CD1d PORT 2 Immune activation 8
Slide 9: PORT-2 Stimulates Multiple Arms of the Immune System
Innate Immune System: Adaptive Immune System: Tumor Microenvironment: Kills cancer cells & increased PD - L1 expression PORT - 2 Stimulates Multiple Arms of the Immune System to Produce a Robust Anti - Cancer Response iNKT cell 9
Slide 10: Multiple Cell Types Needed for Anti-Cancer Response
Target cells NK cell Dendritic cell B - cell CD - 8 T cell MDSC & TAM Antigen Companies in the space PD - 1 PD - L1 Tumor Cell • Upregulates PD - L1 • Monotherapy activity in PD - 1 resistant models • Combo restores sensitivity to PD - 1 Ab + Enhanced activation Multiple Cell Types Needed for Anti -
Slide 11: PORT-2 Demonstrates Robust Single Agent Activity
11 Source: Jukes et al Eur. J. Immunol. 2016. 00: 1 – 11 PORT - 2 Demonstrates Robust Single Agent Activity IMM60 (0.5ng/mouse) PORT - 2 Vehicle + anti PD - 1 Vehicle Untreated PORT - 2 shows better response rates vs. anti - PD - 1 in melanoma model B16 melanoma lung metastases
Slide 12: SITC 2022 - Interim Phase Data Confirms PORT-2 Safety and MOA
SITC 2022 - Interim Phase 1 Data Confirms PORT - 2 Safety and MOA Tumor type 2 Melanoma 4 NSCLC Age 64 (41,79) Median prior therapies 5(3,7) Prior PD - 1 100% Performance status 50% ECOG 0 50% ECOG 1 • MCP - 1 ( Figure 3 ) and IP - 10 ( Figure 4 ) showed increases in most subjects, no increases in I
Slide 13: SITC 2022 - Interim Phase Data Confirms Activity
SITC 2022 - Interim Phase 1 Data Confirms Activity Evidence of monotherapy activity Baseline 3 months Mediastinal Lesion Decreased. 4cm to 1.9cm Additional data in 2023: • High dose cohort of patients receiving PORT - 2 monotherapy • total patients to receive monotherapy (n=18) • Data from cohort of
Slide 14: Multi-arm study with four parallel development paths
Multi - arm study with four parallel development paths = multiple shots on goal 14 Source: https:// www.isrctn.com/ISRCTN80472712 IMPORT - 201: Phase 2 Evaluates Front Line NSCLC and Refractory Melanoma PD - 1 q3wk iv infusions n=15 PD - 1 naïve patients PORT - 2 One dose @ MTD n=15 PORT - 2 + PD -
Slide 15: Adenosine Portfolio
Adenosine Portfolio Validated mechanism impacting multiple immune cells Opportunity to modulate adenosine in 4 different ways: PORT - 6 A2AR Inhibitor PORT - 7 A2BR Inhibitor PORT - 8 A2AR/A2BR Dual Inhibitor PORT - 9 Gut - Restricted A2BR Inhibitor
Slide 16: Leveraging A2A and A2B Alone or in Combo Allows for Customization of Treatment
16 Targeting Adenosine in Cancer Immunotherapy to Enhance T - Cell Function; Virgano, et al; Frontiers in Immunology 2019 modified slightly and used under CC BY 4.0 Leveraging A2A and A2B Alone or in Combo Allows for Customization of Treatment Macrophage Treg T cell NK Cell Endothelial Cell CAF MDSC
Slide 17: Difference in A2A Small Molecules
17 Difference in A2A Small Molecules 10+ hrs Only asset with single agent activity in mouse models Competitive inhibitors won’t block in settings of high adenosine ARCUS CORVUS Potency Selectivity 2.5 hrs Portage’s PORT - 6 is best in class for potency, selectivity and durability Relative profiles o
Slide 18: Fast Follower with Precedent for Biomarker Selection
18 Fast Follower with Precedent for Biomarker Selection * Expression data from Labcorp Probability of Survival 100 50 0 A 2A R low A 2A R h HR=0.45 (0.19 - 1 P=0.02 Tumor type % A2A high* RCC 50 BC 38 NSCLC 34 Gastric 32 Prostate 26 Best % Change in Tumor Lesion by High/ Low A 2A R levels Enrich pat
Slide 19: PORT-7: Highly Selective and Potent A2B Adenosine Receptor Antagonist
19 Data on File PORT - 7: Highly Selective and Potent A2B Adenosine Receptor Antagonist High potency and selectivity may provide important safety and efficacy advantages • Activity in 4T1, CT26, and other disease models (asthma, fibrosis, sickle cell) Binding Affinity Functional Receptor Antagonism
Slide 20: ADPORT-601: Adaptive Phase 1a/1b Study
20 ADPORT - 601: Adaptive Phase 1a/1b Study Phase 1a Starting Dose (10 mg BID) (n=12 - 15) A2AR (PORT - 6) indications: A2BR (PORT - 7) indications: Colorectal Cancer, Non - small Cell Lung Cancer, Endometrial Cancer, Ovarian Cancer with high A2B expression Prostate Cancer, Non - small Cell Lung Can
Slide 21: Strong U.S. and Global IP Positions on Platforms and Products
iNKT Agonists • Composition, formulations with antigens, other I/O agents • Liposomes/particles 2031 - 2036 Patent Exclusivity Many Applications Pending Worldwide Strong U.S. and Global IP Positions on Platforms and Products Broad and deep intellectual property covering: >60 Issued Patents Adenosine
Slide 22: Key Upcoming Clinical Development Milestones
Key Upcoming Clinical Development Milestones* 2023 2024 2025 Q1 Q2 Q3 Q4 1H 2H IMPORT - 201 (PORT - 2) P2 start IMPORT - 201 (PORT - 2) P2 ORR data ADPORT - 601 (Port - 6/7) study activation ADPORT - 601 (Port - 6/7) P1b start IMPORT - 201(PORT - 2) ASCO IMPORT - 201 (PORT - 2) SITC IMPORT - 201 (PO
Slide 23: Summary Financial Data
Summary Financial Data Cash Balance (12/31/22) ~$13.1 million Committed Purchase Lincoln Park Capital Available ^ $29.8 million Debt $ - Shares Outstanding (03/01/23)** 17,403,594 Insider Ownership 50% Public Float* 50% Options & RSUs Outstanding (12/31/22) 1,596,040 Cash Burn During Quarter Ended 1
Slide 24: Accelerating I/O Development in Untapped Growth Areas
Novel, Clinical Stage I/O Portfolio with Small Molecule Focus • Manufacturing simplicity, low capital investment • Nine phase 1b/2 clinical data reads over next 2 years Engine for Efficient Drug Development & Commercialization • Expert scientific oversight • Lean structure with financial flexibility